[1] DESANTIS CE, MA J, GAUDET MM, et al. Breast cancer statistics, 2019[J]. CA Cancer J Clin, 2019, 69(6): 438. doi: 10.3322/caac.21583
[2] CHEN W, ZHENG R, BAADE PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115. doi: 10.3322/caac.21338
[3] 周平, 王亚倩, 李冰, 等. 不同分期肺癌患者术后下肢深静脉血栓形成发生率及凝血指标水平比较[J]. 中华实用诊断与治疗杂志, 2020, 34(1): 59.
[4] JOHNSON ED, SCHELL JC, RODGERS GM. The D-dimer assay[J]. Am J Hematol, 2019, 94(7): 833.
[5] TANAKA N, KIKUCHI E, MATSUMOTO K, et al. Prognostic value of plasma fibrinogen levels in patients with localized upper tract urothelial carcinoma[J]. BJU Int, 2013, 111(6): 857. doi: 10.1111/j.1464-410X.2012.11353.x
[6] KILIC L, YILDIZ I, SEN FK, et al. D-dimer and international normalized ratio (INR) are correlated with tumor markers and disease stage in colorectal cancer patients[J]. Cancer Biomark, 2015, 15(4): 405. doi: 10.3233/CBM-150477
[7] MI XK, LIU QR, ZHU L, et al. Mechanism of the high coagulation state of breast cancer tissue factor[J]. Eur Rev Med Pharmacol Sci, 2017, 21(9): 2167.
[8] SUNG H, FERLAY J, SIEGEL RL, et al. Global Cancer Statistics 2020: GLOBO CAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA Cancer J Clin, 2021, 71(3): 209. doi: 10.3322/caac.21660
[9] BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394. doi: 10.3322/caac.21492
[10] 郑荣寿, 孙可欣, 张思维, 等. 2015年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂, 2019, 41(1): 19. doi: 10.3760/cma.j.issn.0253-3766.2019.01.005
[11] 李江, 杨珂璐, 蔡依彤, 等. 全球乳腺癌筛查指南质量评价[J]. 中华流行病学杂, 2021, 42(2): 219. doi: 10.3760/cma.j.cn112338-20200806-01032
[12] BEVERS TB, HELVIE M, BONACCIO E, et al. Breast cancer screening and diagnosis, version 3.2018, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2018, 16(11): 1362. doi: 10.6004/jnccn.2018.0083
[13] SIU AL, U.S. Preventive Services Task Force. Screening for breast cancer: U.S. preventive services task force recommendation statement[J]. Ann Intern Med, 2016, 164(4): 279. doi: 10.7326/M15-2886
[14] 陈万青, 李霓, 石菊芳, 等. 中国城市癌症早诊早治项目进展[J]. 中国肿瘤, 2019, 28(1): 23.
[15] 黄静, 杨湘红, 刘爱, 等. 农村地区妇女"两癌筛查"项目实施中的问题与对策[J]. 中国全科医学, 2020, 23(13): 1680. doi: 10.12114/j.issn.1007-9572.2019.00.509
[16] 李红, 李朋, 陈震. 乳腺癌发病危险因素的Meta分析[J]. 实用预防医学, 2014, 21(9): 109.
[17] 戴琼, 杜玉开. 女性乳腺癌危险因素的Meta分析[J]. 中华疾病控制杂志, 20110, 14(6): 544.
[18] GREENBERG CS. The role of D-dimer testing in clinical hematology and oncology[J]. Clin Adv Hematol Oncol, 2017, 15(8): 580.
[19] WEITZ JI, FREDENBURGH JC, EIKELBOOM JW. A test in context: D-dimer[J]. J Am Coll Cardiol, 2017, 70(19): 2411. doi: 10.1016/j.jacc.2017.09.024
[20] TINHOLT M, SANDSET PM, MOWINCKEL MC, et al. Determinants of acquired activated protein C resistance and D-dimer in breast cancer[J]. Thromb Res, 2016, 145(1): 78.
[21] CHAARI M, AYADI I, ROUSSEAUA, et al. Impact of breast cancer stage, time from diagnosis and chemotherapy on plasma and cellular biomarkers of hypercoagulability[J]. BMC Cancer, 2014, 14(1): 991.
[22] 陈亮, 李兰丽, 林满遍. FDP、D-二聚体在恶性肿瘤血瘀证腹水患者预后中的意义[J]. 中医药临床杂志, 2018, 30(6): 1115.
[23] 郭志唐, 邹仁超, 柯阳, 等. 肝细胞癌患者术前血浆纤维蛋白原和D-二聚体水平的临床分析[J]. 重庆医学, 2019(13): 2210.
[24] 蒋凤莲, 杨伟洪, 黄文宇. 乳腺癌患者血浆D-二聚体水平与乳腺癌组织中Ki-67表达的相关性[J]. 中国实用医药, 2021, 16(13): 24.
[25] 杨锦, 王倩荣, 张俊美, 等. 美国癌症联合会第8版分期系统对不同分子分型乳腺癌的分期评价及预后判断[J]. 肿瘤研究与临床, 2020, 32(8): 535.
[26] KEY TJ, APPLEBY PN, REEVES GK, et al. Steroid hormone measurements from different types of assays in relation to body mass index and breast cancer risk in postmenopausal women: Reanalysis of eighteen prospective studies[J]. Steroids, 2015, 99(Pt A): 49.
[27] CHOONG GM, CULLEN GD, O'SULLIVAN CC. Evolving standards of care and new challenges in the management of HER2-positive breast cancer[J]. CA Cancer J Clin, 2020, 70(5): 355.
[28] 冯红蕾, 崔林, 李泽, 等. 乳腺癌患者血浆D-二聚体水平与临床病理特征的关系[J]. 山东医药, 2014, 54(42): 8.
[29] DOWSETT M, NIELSEN TO, A'HERN R, et al. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group[J]. J Natl Cancer Inst, 2011, 103(22): 1656.
[30] 杨文涛, 步宏. 乳腺癌雌、孕激素受体免疫组织化学检测指南[J]. 中华病理学杂志, 2015, 44(4): 237.
[31] 杨壹羚, 郭晓静, 付丽. 乳腺癌主要分子病理指标检测结果的解读与分析[J]. 中华病理学杂志, 2020, 49(5): 526.